Biocon will continue to handle the development, manufacture and supply of biosimilar versions of its insulin and insulin analog products, following a deal with Pfizer. Analogs include Recombinant Human Insulin, Glargine, Aspart and Lispro. For its part, Pfizer will commercialize the products globally. Biocon announcement
